+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 65 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are examining how often acute rehabilitation practices are used for children in pediatric intensive care units PICUs. This observational study focuses on children and adolescents admitted to PICUs across 13 hospitals. The main goal is to understand the prevalence and types of rehabilitation care provided during critical care in children aged 18 years or younger. The study does not assign treatments but observes routine clinical rehabilitation practices that children receive as part of their standard care in the PICU. Data will be collected at three specific times spaced about six months apart over an 18-month period to assess how often rehabilitation occurs, the number of sessions, types of interventions, use of assistive devices, and delivery methods. Participants will be monitored through these three seasonal point-prevalence assessments. Researchers will collect detailed information about the rehabilitation sessions, factors affecting whether rehabilitation is provided, and characteristics of the interventions. The total participation period spans these assessments over 18 months, with careful observation but no additional interventions beyond usual care.

Age: 0Days - 18YearsAll Genders
13 locations
P

Actively Recruiting

Researchers are evaluating ELVN-001, an investigational drug, in adults with chronic myeloid leukemia CML, including those with a specific T315I mutation. This early-phase trial aims to find safe and tolerable doses for further study, especially in patients who have relapsed, are resistant, or cannot tolerate current tyrosine kinase inhibitors TKIs. The study also examines how ELVN-001 affects disease markers and its overall safety profile. The trial includes a dose escalation phase to identify recommended doses, followed by dose expansion phases that treat patients with or without the T315I mutation at those doses. ELVN-001 is given orally once or twice daily. Participants receive the drug as a single agent, and the study monitors responses and safety during these phases. Participants will undergo regular assessments including monitoring for side effects, laboratory tests, heart evaluations, and measurement of molecular responses related to CML over periods ranging from 28 days up to 3 years. The study tracks drug levels in the body for up to 6 months and evaluates long-term outcomes such as complete blood responses. Overall participation duration varies, with close safety follow-up throughout.

Age: 18Years +All GendersPhase 1
45 locations
R

Actively Recruiting

Researchers are evaluating whether the combination of pelabresib and ruxolitinib improves clinical outcomes compared to ruxolitinib alone in adults with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have not previously received Janus kinase inhibitor therapy. This phase 3 trial aims to assess treatment effects on spleen size and symptom scores using a randomized, double-blind design. Participants receive pelabresib or placebo orally once daily for 14 days in each 21-day cycle alongside continuous twice-daily oral ruxolitinib during the treatment period. The treatment continues until unacceptable side effects, disease progression, or withdrawal. The study includes a screening phase, a safety follow-up lasting about 30 days after last dose, an efficacy follow-up every 12 weeks for those without disease progression, and a survival follow-up with remote visits every 12 weeks for participants who progress or start new therapies. During the study, participants undergo regular assessments including spleen imaging by CT or MRI, laboratory tests, bone marrow biopsies, and symptom questionnaires. Researchers measure spleen response and symptom score changes at 24 weeks and continue monitoring multiple outcomes such as survival, anemia, and quality of life for up to three years. Safety is closely followed during and after treatment to observe any adverse events or late effects.

Age: 18Years +All GendersPhase 3
163 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
S

Actively Recruiting

This research aims to learn about the safety and effects of a medicine called ritlecitinib for treating moderate alopecia areata AA, a condition causing patchy hair loss. The study includes participants aged 12 years and older who have had patchy hair loss for at least 6 months but not more than 10 years, without other causes of hair loss. It is a phase 3 randomized, double-blind, placebo-controlled trial designed to evaluate ritlecitinib in adolescents and adults with AA. Participants will be randomly assigned to receive either ritlecitinib 50 mg or placebo once daily by mouth for 24 weeks. After this, depending on their response, their treatment may remain the same or change to either 50 mg or 100 mg ritlecitinib for another 23 weeks. Those receiving placebo initially may also be switched to ritlecitinib during this second period. Treatments are taken at home, and the study includes multiple groups based on response to treatment. Participants will be involved for about 57 weeks, including study visits at the clinic and some phone check-ins. Researchers will monitor hair loss using the Severity of Alopecia Tool SALT and other assessments like eyebrow and eyelash evaluations, patient satisfaction, and emotional impact. Safety will be closely monitored through adverse event tracking and laboratory tests. A follow-up visit about 4 weeks after the last dose will check on participants health.

Age: 12Years +All GendersPhase 3
38 locations
R

Actively Recruiting

Researchers are evaluating the safety and effects of ritlecitinib, a medicine taken by mouth, for treating alopecia areata, a condition causing hair loss on the scalp, face, and other body areas. This study focuses on people 12 years and older who have lost 50% or more of their scalp hair and do not have other causes of hair loss. The study aims to compare two doses, 50 mg and 100 mg, of ritlecitinib and see if the higher dose is safe and effective. Participants in Part 1 are randomly assigned to receive either 50 mg or 100 mg of ritlecitinib once daily, with some re-randomization at 24 weeks based on their response. Part 2 includes adolescents aged 12 to less than 18 years who receive 100 mg once daily. The study compares these doses to each other and to data from previous studies without a placebo group within this trial. Participants take the study medicine by mouth daily for up to 48 weeks depending on their group. During the approximately 13-month study, participants visit the study site up to nine times for assessments including alopecia areata evaluations, physical exams, hearing tests, blood tests, chest X-rays, electrocardiograms, and scalp and eye photographs Part 1 only. They also complete questionnaires about their condition. Researchers measure hair loss severity using the Severity of Alopecia Tool SALT, monitor side effects, laboratory results, and overall safety throughout the trial.

Age: 12Years +All GendersPhase 3
148 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of baricitinib in treating severe or very severe alopecia areata, a type of hair loss, in children aged 6 to less than 18 years. This Phase 3 trial includes children and adolescents with severe alopecia areata lasting at least one year and aims to understand how baricitinib helps improve their condition compared to placebo. Participants will be randomly assigned to one of three groups baricitinib high dose, baricitinib low dose, or placebo, all taken orally. The study includes a 5-week screening period, a 36-week double-blind treatment period, an approximately 2-year long-term extension period, and a 4-week post-treatment follow-up. Some participants may qualify for additional treatment after the extension period lasting up to 180 weeks. During the study, participants will have regular assessments including hair loss severity scores, patient and clinician reported outcomes, anxiety and depression scales, and pharmacokinetic tests. Safety and effects on quality of life will be monitored throughout, with follow-ups after treatment ends. Total participation may last several years depending on the study phase and extension.

Age: 6Years - 17YearsAll GendersPhase 3
127 locations
P

Actively Recruiting

Researchers are evaluating treatments for newly diagnosed multiple myeloma in patients who cannot undergo autologous stem cell transplantation. This Phase 3 study compares two drug combinations belantamab mafodotin with lenalidomide and dexamethasone BRd versus daratumumab with lenalidomide and dexamethasone DRd. The goal is to see if BRd extends progression-free survival and improves minimal residual disease negative status compared to DRd. Participants receive either BRd or DRd treatment, continuing until disease progression, death, unacceptable side effects, withdrawal, or study end. Both treatment arms involve the administration of lenalidomide and dexamethasone alongside either belantamab mafodotin or daratumumab. Treatment duration may last up to approximately seven years. During the study, participants will undergo regular assessments including monitoring disease progression, response to treatment, and side effects. Measurements include progression-free survival, overall survival, and the number achieving minimal residual disease negative status. Quality of life questionnaires and blood tests will also be conducted. Safety monitoring includes eye exams and tracking adverse events throughout the study duration.

Age: 18Years +All GendersPhase 3
181 locations
S

Actively Recruiting

This research aims to collect and evaluate safety and effectiveness information about Jyseleca tablet Filgotinib Maleate 100 mg and 200 mg in Korean participants using it in real-world conditions. The study focuses on monitoring serious and non-serious adverse events and drug reactions, including unexpected ones, as well as changes in disease activity scores related to rheumatoid arthritis and ulcerative colitis. Participants prescribed Jyseleca according to Korean approved therapeutic indications will be observed without additional intervention. They will be followed for up to 24 weeks or until they stop treatment due to adverse events or other reasons. The study includes adults with rheumatoid arthritis or ulcerative colitis who have not responded well or are intolerant to prior treatments. During the study, researchers will track adverse events and reactions from enrollment through 24 weeks. They will also measure changes in disease activity scores at baseline, week 12, and week 24. Participants will have regular monitoring visits as part of their usual care, with data collected about safety and treatment effects. The total participation time is up to 24 weeks.

Age: 18Years +All Genders
59 locations
E

Actively Recruiting

Researchers are evaluating the effects of LY4005130 in adults with severe alopecia areata, a condition causing significant hair loss. This Phase 2 study aims to compare LY4005130s impact with a placebo, focusing on how well the drug works, how well it is tolerated, and what side effects may occur. Blood tests will also be conducted to understand how the drug is processed by the body and its biological effects. Participants will receive LY4005130 or placebo intravenously IV into a vein in the arm. The study uses a randomized, double-blind, placebo-controlled design to compare the study drug with placebo. The entire study duration is about 48 weeks, including a screening period. The main treatment phase assesses responses over 24 weeks, with additional follow-up for safety and drug effects. During the study, participants will undergo regular assessments including the Severity of Alopecia Tool SALT to measure hair loss improvement. Blood samples will be collected to analyze drug levels and gene expression changes in scalp biopsies. The study will monitor side effects and overall safety, helping researchers understand the treatments effects over nearly a year of participation.

Age: 18Years - 60YearsAll GendersPhase 2
30 locations

1-10 of 65

1